Solid Biosciences
SLDB
92 hedge funds and large institutions have $293M invested in Solid Biosciences in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 25 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 23
48% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $748K
0.06% more ownership
Funds ownership: 4.79% → 4.85% (+0.06%)
12% less funds holding
Funds holding: 104 → 92 (-12)
33% less capital invested
Capital invested by funds: $437M → $293M (-$144M)
48% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 25
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.02M |
| 2 |
Two Sigma Advisers
New York
|
+$3.52M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.87M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.47M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$10.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$5.98M |
| 3 |
Barclays
London,
United Kingdom
|
-$2.58M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$1.77M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$723K |
SLDB Hedge Fund Activity: Q2 2021 in Review
92 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2021, worth a combined $293M — down 33% from $437M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of SLDB and 13 opened new positions — a net loss of 12 holders — while 23 trimmed existing stakes and 37 added.
The largest buyer was BlackRock, adding an estimated $7.02M. The largest seller was Citadel Advisors, cutting an estimated $10.9M.
- 92 institutional investors held Solid Biosciences (SLDB) as of Q2 2021, down from 104 in Q1 2021.
- Funds reported $293M of Solid Biosciences stock for Q2 2021, down 33% quarter-over-quarter.
- 13 funds opened new Solid Biosciences positions in Q2 2021 and 25 closed out, a net change of -12 holders.
- The largest Solid Biosciences buyer in Q2 2021 was BlackRock, an estimated $7.02M added.
- The largest Solid Biosciences seller in Q2 2021 was Citadel Advisors, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2021.